MA52495A - Nouveau traitement de maladies pulmonaires interstitielles - Google Patents

Nouveau traitement de maladies pulmonaires interstitielles

Info

Publication number
MA52495A
MA52495A MA052495A MA52495A MA52495A MA 52495 A MA52495 A MA 52495A MA 052495 A MA052495 A MA 052495A MA 52495 A MA52495 A MA 52495A MA 52495 A MA52495 A MA 52495A
Authority
MA
Morocco
Prior art keywords
new treatment
pulmonary diseases
interstitial pulmonary
interstitial
diseases
Prior art date
Application number
MA052495A
Other languages
English (en)
Inventor
Carl-Johan Dalsgaard
Adam Feiler
Paulina Paszkiewicz
Xin Xia
Chunfang Zhou
Original Assignee
Inim Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inim Pharma Ab filed Critical Inim Pharma Ab
Publication of MA52495A publication Critical patent/MA52495A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5115Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/695Silicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA052495A 2018-05-03 2019-05-03 Nouveau traitement de maladies pulmonaires interstitielles MA52495A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1807286.8A GB201807286D0 (en) 2018-05-03 2018-05-03 New use

Publications (1)

Publication Number Publication Date
MA52495A true MA52495A (fr) 2021-03-10

Family

ID=62598220

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052495A MA52495A (fr) 2018-05-03 2019-05-03 Nouveau traitement de maladies pulmonaires interstitielles

Country Status (14)

Country Link
US (1) US20210236425A1 (fr)
EP (1) EP3787599A1 (fr)
JP (1) JP2021522352A (fr)
KR (1) KR20210003779A (fr)
CN (1) CN112469395A (fr)
AU (1) AU2019263701A1 (fr)
BR (1) BR112020022363A2 (fr)
CA (1) CA3099008A1 (fr)
EA (1) EA202092396A1 (fr)
GB (1) GB201807286D0 (fr)
MA (1) MA52495A (fr)
MX (1) MX2020011474A (fr)
SG (1) SG11202010585WA (fr)
WO (1) WO2019211624A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201916121D0 (en) 2019-11-06 2019-12-18 Vicore Pharma Ab New compositions
GB201916117D0 (en) 2019-11-06 2019-12-18 Vicore Pharma Ab New compositions
GB201916130D0 (en) 2019-11-06 2019-12-18 Vicore Pharma Ab New compositions
GB201916122D0 (en) 2019-11-06 2019-12-18 Nanologica Ab New compositions
GB202012152D0 (en) 2020-08-05 2020-09-16 Vicore Pharma Ab New compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
WO2002015928A1 (fr) * 2000-08-18 2002-02-28 Medimmune, Inc. Methode d'administration d'une proteine fimh en tant que vaccin contre les infections de infections urinaires
GB0118689D0 (en) 2001-08-01 2001-09-19 Psimedica Ltd Pharmaceutical formulation
AU2002364701B8 (en) 2001-11-20 2006-06-22 Alkermes, Inc. Compositions for sustained action product delivery
WO2007075680A2 (fr) * 2005-12-19 2007-07-05 University Of Vermont And State Agricultural College Systeme et procede d'administration d'un materiau a une cellule
WO2012035074A1 (fr) 2010-09-14 2012-03-22 Nanologica Ab Véhicules d'administration à sursaturation pour principes actifs pharmaceutiques et cosmétiques faiblement hydrosolubles
DK2948148T3 (da) * 2013-01-28 2020-10-26 Incozen Therapeutics Pvt Ltd Metoder til behandling af autoimmune, åndedræts- og betændelsesforstyrrelser ved inhalation af roflumilast n-oxid
WO2016054225A1 (fr) * 2014-09-30 2016-04-07 Stc.Unm Administration de plasmide dans le traitement du cancer et d'autres problèmes de santé
EP3233059A1 (fr) 2014-12-19 2017-10-25 Synthon B.V. Composition pharmaceutique comprenant du lenalidomine amorphe

Also Published As

Publication number Publication date
EP3787599A1 (fr) 2021-03-10
CA3099008A1 (fr) 2019-11-07
JP2021522352A (ja) 2021-08-30
US20210236425A1 (en) 2021-08-05
GB201807286D0 (en) 2018-06-20
WO2019211624A1 (fr) 2019-11-07
KR20210003779A (ko) 2021-01-12
BR112020022363A2 (pt) 2021-02-02
EA202092396A1 (ru) 2021-05-21
MX2020011474A (es) 2021-02-18
AU2019263701A1 (en) 2020-11-12
SG11202010585WA (en) 2020-11-27
CN112469395A (zh) 2021-03-09

Similar Documents

Publication Publication Date Title
IL276383A (en) Treatment of ophthalmological diseases
MA52495A (fr) Nouveau traitement de maladies pulmonaires interstitielles
EP3634442A4 (fr) Méthodes de traitement et de prévention de maladies
EP3658139A4 (fr) Méthodes de traitement de maladies hépatiques
EP3720553C0 (fr) Dispositif de photobiomodulation destiné au traitement d'une maladie rétinienne
EP3442577A4 (fr) Traitement de maladies oculaires avec un fab anti-vegf à modification post-traductionnelle totalement humain
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP3273955A4 (fr) Traitement de maladies respiratoires
IL284125A (en) Quinoline derivatives for use in the treatment of inflammation diseases
FR25C1031I1 (fr) Traitement de maladies cholestatiques intrahepatiques
MA46061A (fr) Traitement ascaroside de maladies auto-immunes et inflammatoires
IL269363A (en) Methods for measuring therapeutic effects of retinal disease therapies
EP2945616A4 (fr) Traitement de maladies pulmonaires
MA42930A (fr) Traitement de maladies neurodégénératives
MA44126A (fr) Méthodes de traitement de maladies et troubles pulmonaires
EP3737379A4 (fr) Compositions et méthodes de traitement de maladies métaboliques
EP3344258A4 (fr) Traitement de maladies auto-immunes et de maladies auto-inflammatoires
MA41462A (fr) Méthode de traitement de maladies
EP3664789A4 (fr) Méthodes de traitement de maladies et de lésions des nerfs
ZA202101587B (en) Protein for treatment of inflammatory diseases
EP3737363A4 (fr) Méthodes de traitement de maladies inflammatoires chroniques
MA53986A (fr) Traitement de maladies neurologiques avec du zilucoplan
IL270900A (en) Treatment of cutaneous disorders
GB201805100D0 (en) Treatment of sarcopenic diseases
EP3658217A4 (fr) Traitement de troubles oculaires